Developing longer-lasting eye drops for glaucoma treatment
Official title: Pharmaceutical development of longer-lasting brimonidine eye drops
Funded at Novus Vision LLC · NIH-10932173 · Data updated 2026-11-12
This study is testing a new eye drop called OcuGel that helps lower eye pressure for people with glaucoma and is designed to be used less often, making it easier and more comfortable for patients to stick to their treatment.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Novus Vision LLC NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | September 30, 2023 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $964,469 |
| NIH project number | 5R44EY035177-02 |
| Project ID | NIH-10932173 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with glaucoma who require medication to manage their intraocular pressure.
✕Less likely to help
Patients who do not have glaucoma or those who are not experiencing issues with current glaucoma treatments may not benefit from this research.
What this research studies
This research focuses on creating a new type of eye drop that can effectively lower intraocular pressure in glaucoma patients while being used less frequently than current treatments. The innovative eye drop, called OcuGel, is designed to be liquid at room temperature but transforms into a gel upon application, ensuring that the medication stays in place longer and provides relief from dry eye symptoms. By reducing the frequency of dosing, the study aims to improve patient adherence to treatment and overall eye health. The approach combines advanced drug delivery technology with a focus on patient comfort and compliance.
Why it matters
Potential benefit: If successful, this research could lead to more effective glaucoma management with fewer daily doses, improving patient adherence and reducing the risk of vision loss.
How similar studies have gone: Previous research has shown promise in developing sustained-release formulations for ocular medications, indicating potential success for this novel approach.
Where this research is happening
-
Novus Vision LLC
Baltimore, United States Active
Researchers
- Principal investigator: Hsueh, Tung Heng — Novus Vision LLC
- Study coordinator: Hsueh, Tung Heng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.